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Background: Non-adherence to antipsychotic medication in schizophrenic patients is common and associated with
symptom relapse and poorer long-term outcomes. The risk factors for treatment non-adherence include dosing
frequency and complexity. Besides, slower dose titration in an acute schizophrenic episode may lead to attenuated
efficacy. Therefore, the convenient dosage regimen and rapid initiation scheme of quetiapine extended release (XR)
were expected to provide better effectiveness and promote adherence in patients with schizophrenia. This study was
implemented to assess the efficacy and safety of once-daily quetiapine XR in schizophrenic patients with switched from
other antipsychotics which were suboptimal due to insufficient efficacy or tolerability.
Methods: This was a 12-week, open-label study conducted in the Chinese population in Taiwan.
Patients who had a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome
Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics were recruited.
Quetiapine XR was administered at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until
the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical
response and tolerance of the patients. The variable of the primary outcome was the change from baseline to Week 12
in PANSS total and subscale scores. Secondary outcome was the baseline-to-endpoint difference in the Clinical Global
Impression-Severity (CGI-S) scores of the participants.
Results: Sixty-one patients were recruited and 55.7% of them completed the study. The mean changes in the PANSS
total score and CGI-S score showed significant improvement (−18.4, p < .001 and −1.0, p < .001, respectively). Four
patients (6.7%) experienced adverse events including headache, exacerbation of psychosis and dysuria. The use of
concomitant anticholinergics decreased from 15.0% to 8.3%.
Conclusions: The results of our investigation implicated that quetiapine XR was an effective and well tolerated
alternative for Chinese schizophrenic patients with previous suboptimal treatment. Future large-scale studies are
warranted to validate our results.
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Antipsychotics have long been established as a necessary
part of pharmacotherapeutic interventions in both acute
and long-term treatment of schizophrenia to control the
disturbed symptoms, reduce the risk of harm, and help
the patients to regain their premorbid level of function-
ing [1-4]. Non-adherence to antipsychotic medication in
schizophrenic patients has also been considered to be a
crucial contributor to symptom relapse and poorer long-
term outcomes [5-7]. However, it is common for patients
with schizophrenia to have low adherence to antipsy-
chotics [8-10] and it had been reported that almost half of
schizophrenic patients took less than 70% of the expected
prescribed doses [11]. The risk factors for treatment non-
adherence include poor therapeutic response, adverse
events related to antipsychotic medication, impaired
insight, comorbid substance abuse, negative attitude to-
wards treatment, and dosing frequency and complexity
[11-14]. Although the current atypical antipsychotics show
comparable efficacy and better tolerability [1,2], it is still
challenging in clinical practice to improve the treatment-
adherence in schizophrenic patients.
For acute schizophrenic episode, it is important to pro-
vide treatment in order to achieve an early response
within the first several days [15,16]. Early improvement is
associated with better subsequent symptom response and
less illness chronicity [17,18]. To reach the goal of prompt
symptom reduction, rapid dose escalation of antipsy-
chotics had been recommended as a beneficial treatment
strategy for acutely ill schizophrenic patients [16,19-23].
On the other hand, slower dose titration in an acute
schizophrenic episode may lead to attenuated efficacy
[24,25]. Accordingly, the administration of the well toler-
ated antipsychotics which could be rapidly titrated to tar-
get dosage is critical for acute schizophrenic patients.
Extended-release quetiapine fumarate (quetiapine XR) is
a formulation with similar bioavailability to immediate-
release quetiapine fumarate (quetiapine IR) [26]. Que-
tiapine XR also achieved comparable mean plasma
concentrations as quetiapine IR, which was recom-
mended two divided doses regimen, during a 24 h dos-
ing interval when administered once daily [26]. Besides,
the milder sedative profile of quetiapine XR [27] may
be more suitable for fast initiation than quetiapine IR,
which had been reported that more patients experi-
enced somnolence and postural hypotension with the
treatment of rapid dose escalation [28]. Therefore, this
convenient dosage regimen and rapid initiation scheme
with quetiapine XR were expected to provide better ef-
fectiveness and promote adherence in patients with
schizophrenia [29,30]. It has been demonstrated that
quetiapine XR is efficacious and safe in treating acute
schizophrenic episodes [31,32] and in preventing symp-
tom relapse [33,34]. In addition, two previous trialsreported positive outcomes of switching to quetiapine
XR from other antipsychotics in patients with subopti-
mal prior pharmacological treatment [35,36]. However,
there was still a paucity of clinical investigation about
the efficacy and tolerability of quetiapine XR in a Chinese
population with schizophrenia. For the significant lower
prevalence rate of schizophrenic patients [37,38] and dif-
ferent metabolism of psychotropic agents [39,40], the
Chinese should be considered as a specific ethnic popula-
tion in the investigation of the effectiveness of antipsy-
chotics. Here we implemented a 12-week, open label study
to assess the clinical benefit of switching to quetiapine XR
in the Chinese schizophrenic patients in Taiwan who were
dissatisfied with their ongoing antipsychotic therapy.
Methods
Patients
The participants who were aged from 20 to 65 years and
met the diagnostic criteria for schizophrenia according to
the Diagnostic and Statistical Manual of Mental Disorders,
fourth edition, text revision (DSM-IV-TR) were eligible
for recruitment in this clinical trial. All of them were
screened at the psychiatric outpatient or acute ward of the
principal investigator’s affiliation which was a medical uni-
versity hospital. The subjects had a score of 4 (moderate)
or greater on any of the 7 items of the Positive and Nega-
tive Syndrome Scale (PANSS) Positive Symptom Subscale
and needed to switch from previous antipsychotics due to
insufficient efficacy or tolerability (intolerable adverse
events reported by the patient or observed by the principal
investigator). Any of the following was regarded as a cri-
terion for exclusion from the study: (1) any DSM-IV-TR
Axis I disorder other than schizophrenia, except comorbid
obsessive-compulsive disorder, anxiety disorder, eating
disorder or impulse control disorder if they had been
stable and these had not been the primary focus of treat-
ment over the previous 6 months; (2) an imminent risk of
suicide or a danger to self or others; (3) pregnancy or lac-
tation; (4) intolerance or lack of response to quetiapine IR;
(5) use of cytochrome P450 3A4 inhibitors or inducers in
the 14 days preceding enrollment; (6) administration of a
depot antipsychotic injection within one dosing interval
before recruitment; (7) unstable or inadequately treated
medical illness as judged by the investigator. Before re-
cruitment, all of the patients provided written informed
consent after the study had been thoroughly explained to
them. The study was approved by the Institutional Review
Board of Tri-Service General Hospital, National Defense
Medical Center, Taipei, Taiwan.
Study design
This study was a 12-week, open-label investigation con-
ducted in the Chinese population in Taiwan (November
2008 to March 2012). The treatment was initiated with a
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medication was maintained at the original dose from
day 1 to day 3; then reduced to 50% of the original dose
from day 4 to day 7 and discontinued on day 8. Mean-
while, the patients started the study medication with a
daily dose of 300 mg on day 1, 600 mg on day 2 and up
to 800 mg after day 2. From day 8 until the end of the
study (treatment period), the dose of study medication
was adjusted within the effective dose range of 400 mg
to 800 mg per day, depending on the clinical response
and tolerance of the patient. The administration of any
other antipsychotics or psychoactive medications was
prohibited during the treatment period. Patients treated
with quetiapine IR preceding enrollment were direct
switched to the equivalent dose of quetiapine XR. The
dose and treatment regimen of this study are shown in
Figure 1.
Efficacy assessments
The variable of the primary endpoint was the change from
baseline to Week 12 in PANSS total and subscale scores.
Patients were evaluated at other three visits with PANSS
during the study period, including week 1, week 4 and
week 8. Another efficacy endpoint was the difference from
baseline to the end of the study in the Clinical Global
Impression-Severity (CGI-S) scores of the participants.
Safety assessments
The occurrence and severity of adverse events (AEs) was
recorded throughout the study to assess the tolerability of
quetiapine XR, including AEs spontaneously reported by
the patients or observed by the staff after interviewing the
patient. We used Abnormal Involuntary Movement
Scale (AIMS), Barnes-Akathisia Rating scale (BARS)
and Simpson-Angus Scale (SAS) to evaluate the extra-
pyramidal symptoms (EPS) associated with the previous
antipsychotics or quetiapine XR. The use of anticholin-
ergic medications in each patient during the treatment
period was also recorded.Figure 1 The study design and schematic diagram of switching from
aAfter day 2, the dosage of quetiapine XR was allowed up to 800 mg. From d
effective dose range of 400 mg to 800 mg per day.Each patient’s vital signs and body weight were mea-
sured at screening and at every scheduled visit (week 1,
2, 4, 8, 12). The electrocardiogram (ECG) and laboratory
measurements including hematology and glycosylated
hemoglobin (HbA1c) were performed at enrollment and
at week 12.
Adherence to the study medication was evaluated by
measuring the difference between the dosage dispensed
and the tablets returned at each scheduled visit. Patients
who took more than 85% dosage of the study drugs as
prescribed were considered to be treatment adherent.
Statistical analysis
The intention-to-treat (ITT) population, consisting of all
patients who took at least one dose of the study medica-
tion and had at least one evaluation for the primary effi-
cacy endpoint after the cross titration period, was used
for the efficacy and safety assessment. Subgroup analyses
based on the reasons for switching and the previous
antipsychotic treatment were also performed. A last ob-
servation carried forward (LOCF) approach was applied
to handle the missing values for the efficacy analysis. To
compare the baseline characteristics between the two
subgroups with different reasons for enrolling, the chi-
square test or Fisher’s exact test were used for categorical
variables and Student’s t test for continuous variables. For
the primary and the other efficacy endpoints, a two-way
ANOVA with one-way repeated was used to analyze the
mean change in PANSS and CGI-S scores between
groups. A p value of less than 0.05 was considered to be
statistically significant. All statistical analyses were
performed with SPSS software version 17 (SPSS Inc.,
Chicago, IL, USA).
Results
Patient disposition and characteristics
A total of 61 patients (45 patients from the psychiatric
outpatient and 16 patients from the acute ward) were re-
cruited in the study and one discontinued before receivingother antipsychotics to quetiapine XR in this investigation.
ay 8 until week 12, the dose of quetiapine XR was adjusted within the
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one dose of quetiapine XR were included in the intention-
to-treat (ITT) population. Among them, 39 patients
(65.0%) were recruited because of insufficient response
and 21 patients (35.0%) because of insufficient tolerance
to their original antipsychotics. During the 12-week
follow-up period, 26 patients discontinued the study pre-
maturely. The reasons were lost to follow up (14 patients),
consent withdrawal (11 patients) and adverse events (1 pa-
tient). Thirty-four patients (55.7%) completed the study
(Figure 2).
In terms of the patients’ previous antipsychotics, 15 pa-
tients (25.0%) received risperidone (2.99 ± 1.44 mg [mean
daily dose ± standard deviation]), 11 (18.3%) quetiapine
IR (445.45 ± 103.57 mg), 9 (15.0%) sulpiride (511.11 ±
105.41 mg), 6 (10.0%) amisulpride (480.00 ± 228.04 mg), 5
(8.3%) olanzapine (10.63 ± 7.18 mg), 5 (8.3%) aripiprazole
(8.50 ± 3.35 mg), 4 (6.7%) ziprasidone (90.00 ± 50.33 mg)
and 3 (5.0%) clozapine (62.50 ± 45.07 mg). One patient re-
ceived aripiprazole and clozapine combination therapy;
one received no antipsychotics before entering the trial
and two did not report their prior antipsychotics.
The patients’ baseline demographics and clinical char-
acteristics of the two subgroups were generally equiva-
lent except that the patients who switched because of
insufficient tolerance were younger than those recruited
because of insufficient response (33.3 years vs. 40.5 years,
t = 2.595, p = .012) (Table 1).
Treatment
The mean number of days of exposure to quetiapine XR
was 56.63 ± 35.18 (mean ± standard deviation) for allFigure 2 Patient disposition during the study.patients and there was no significant difference between
the two subgroups. The mean daily dose of quetiapine
XR was 562.50 ± 177.81 mg, which was comparable be-
tween the two populations. During the follow-up period,
a total of 52 patients (86.7%) were considered to be
treatment adherent and 4 patients took less than 70.0%
dosage of the study drugs as ordered. The mean adher-
ence rates between the two subgroups were similar.
Efficacy
The overall population’s PANSS total score and subscale
scores were significantly improved at the week 12 evalu-
ation. The mean changes from baseline to the end of the
study (based on estimated marginal means) in PANSS
total and the positive, negative and general psychopath-
ology subscale scores were −18.4 (95% CI −22.6, −14.2;
p < .001), −5.8 (95% CI −7.1, −4.4; p < .001), −5.0 (95%
CI −6.4, −3.6; p < .001) and −7.6 (95% CI −9.6, −5.7;
p < .001), respectively (Figure 3). Figure 4 showed the time
response curve according to the improvement of PANSS
total score from baseline to each visit.
The patients subdivided according to the reasons for
switching also showed significant reductions in PANSS
total and subscale scores with no statistical difference
between the two subgroups. When we analyzed the effi-
cacy of quetiapine XR based on the patients’ previous
antipsychotic treatments, there was also a significant im-
provement in PANSS total and subscale scores irrespect-
ive of their prior medication. The mean changes in
PANSS total scores in patients treated with different an-
tipsychotics before switching were risperidone −17.7 ±
13.9 (mean ± standard deviation), quetiapine IR −27.6 ±
Table 1 Patient demographics and clinical characteristics at baseline
Overall (n = 60) Insufficient response (n = 39) Insufficient tolerability (n = 21)
Gender, n (%)
Male 37 (61.7) 22 (56.4) 15 (71.4)
Female 23 (38.3) 17 (43.6) 6 (28.6)
Age, years (SD)c 38.0 (10.7) 40.5 (10.5)* 33.3 (9.9)*
Marital status, n (%)a
Single 42 (70.0) 25 (64.1) 17 (81.0)
Married 11 (18.3) 9 (23.1) 2 (9.5)
Divorced 4 (6.7) 3 (7.7) 1 (4.8)
Widowed 2 (3.3) 2 (5.1) 0 (0.0)
Employment status, n (%)a
Employed 12 (20.0) 8 (20.5) 4 (19.0)
Student/Retired 4 (6.7) 1 (2.6) 3 (14.3)
Unemployed 43 (71.7) 30 (76.9) 13 (61.9)
Psychiatric history
Disease duration, years (SD) 12.5 (9.3) 13.2 (9.6) 11.3 (8.8)
Number of schizophrenic episodes over lifetime, n (SD) 3.6 (2.7) 3.2 (2.1) 4.3 (3.5)
Presence of family members with schizophrenia, n (%) 9 (15.0) 4 (10.3) 5 (23.8)
Psychoactive medication at base, n (%)
Any antipsychotics 59b (98.3) 38b (97.4) 21 (100.0)
Risperidone 15 (25.0) 8 (20.5) 7 (33.3)
Quetiapine IR 11 (18.3) 8 (20.5) 3 (14.3)
Sulpiride 9 (15.0) 8 (20.5) 1 (4.8)
Amisulpride 6 (10.0) 3 (7.7) 3 (14.3)
Aripiprazole 5 (8.3) 3 (7.7) 2 (9.5)
Olanzapine 5 (8.3) 3 (7.7) 2 (9.5)
Ziprasidone 4 (6.7) 3 (7.7) 1 (4.8)
Clozapine 3 (5.0) 1 (2.6) 2 (9.5)
Mean (SD) baseline scores
PANSS 84.4 (17.7) 85.9 (17.5) 81.7 (18.2)
CGI-S 4.7 (0.7) 4.7 (0.7) 4.7 (0.7)
aOne patient with insufficient tolerance had no reported marital status and employment status.
bOne patient with insufficient response had received no antipsychotics before entering the trial; Two patients did not report their previous antipsychotics.
*p < .05, ct test = 2.595, p = .012
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−24.6 ± 14.4.
There was a significant improvement in CGI-S score in
the overall population (mean change −1.0; 95% CI −1.3,
−0.8; p < .001), the patients switching for insufficient re-
sponse (mean change −1.2; 95% CI −1.6, −0.9; p < .001),
and the patients recruited due to insufficient tolerability
(mean change −0.9; 95% CI −1.3, −0.4; p < .001).
Tolerability
AEs
During our study, quetiapine XR was well tolerated with-
out severe AEs. Four patients (n = 4/60, 6.7%) experiencedAEs of mild to moderate severity. One patient had head-
aches, two patients showed exacerbation of psychosis, and
the other patient had difficulty in urination that she was
discontinued from study. There were no deaths during the
study.
EPS
Throughout the treatment period, quetiapine XR was
found well tolerated by all patients receiving the medica-
tion. Only one patient was noted to have akathisia rated 1
on all four items of the BARS and muscle rigidity rated 1
on the item head dropping of SAS at week 4. Her symp-
toms resolved spontaneously without administration of
Figure 3 Changes in PANSS total and subscale scores from
baseline to week 12 in patients with schizophrenia receiving
the treatment of switching to quetiapine XR. The change in
PANSS total and subscales score in all patients shown is based on
estimated marginal means. *p < .05.
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there were no obvious objective or subjective extrapyram-
idal symptoms observed during the treatment with quetia-
pine XR. The proportion of patients taking concomitant
anticholinergics was 15.0% on day 1 and decreased to
8.3% at the end of the study.
Laboratory data, vital signs and physical findings
All patients’ pulse rates, blood pressure, hematology,
HbA1c and ECG parameters showed no significant
changes from enrollment to week 12 assessments. The pa-
tients’ baseline mean body mass index (BMI) was 25.4 ±
3.7 kg/m2 with 30.0% of the patients overweight (BMI ≥
24) and 30% obesity (BMI ≥ 27). (according to the ad-
justed definition of the Health Promotion Administration,Figure 4 Changes in PANSS total score from baseline to W1,
W4, W8 and W12 in patients with schizophrenia after switching
to quetiapine XR. The change in PANSS total score in all patients
shown is based on estimated marginal means. *p < .05.Ministry of Health and Welfare, Taiwan.) The mean
change in all patients’ body weight from baseline to the
end of the study was 0.0 kg. The patients’ mean BMI at
week 12 was 25.4 ± 3.7 kg/m2 with 31.7% of the patients
overweight and 28.3% obesity. No patient reported more
than a 7.0% change in body weight.
Discussion
Consistent with the previous study that the response in
the first three days predicted the symptoms remission
4 weeks later in the patients with schizophrenia [41], our
study demonstrated the effectiveness and good tolerabil-
ity of the extended release (XR) fumarate of quetiapine
administered with forced dosage titration from 300 to
800 mg within the first three days in a Chinese popula-
tion after treatment with a 12-week study period. Our
results showed that the patients’ PANSS total and each
subscale score showed significant improvement from
baseline irrespective of the reasons for enrollment in the
study or prior antipsychotics. A significant reduction
was also observed in the mean change from baseline in
CGI-S scores. These findings provided supporting evi-
dence that quetiapine XR was an effective therapeutic al-
ternative for acute schizophrenic episodes. Our data was
consistent with that of two previous multicenter clinical
trials conducted in countries other than Taiwan [35,36],
and suggested that quetiapine XR demonstrated compar-
able effectiveness in Chinese schizophrenic patients.
The titration scheme for quetiapine XR in this study
reached a therapeutic dose within three days through
initiation of therapy at a higher dose. The switching
paradigm had been adopted in other studies [32,35,36]
and also showed benefit in the present investigation. It
has been found that the extended release formulation re-
sulted in similar mean plasma levels but decreased fluctu-
ations when compared to immediate release quetiapine
[26,29]. That may improve tolerability and allow rapid ti-
tration to the target regimen in order to achieve an early
response which was considered to be a predictor for the
subsequent symptom improvement and a better outcome
[17,42]. Besides, the advantages of this switching paradigm
also included a reduction of the risk of additive side effects
by shortening the period of cross-tapering [43]. Further-
more, the simplified dosing regimen of taking medication
only once daily was thought to correlate with potentially
better adherence [13,44-46] and a beneficial impact on
long-term functional outcomes [5].
Our results indicated that quetiapine XR was generally
well tolerated by participants, even in the first week
when they underwent rapid dosage escalation to a thera-
peutic dose. It may be attributed to quetiapine XR’s
pharmacokinetics which skip the high peak plasma con-
centration found in quetiapine IR [26] and therefore re-
duce the risk of side effect. This suggested that quetiapine
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schizophrenic episode since the high loading dose might
have faster efficacy but have a lower incidence of adverse
events such as postural hypotension, somnolence and diz-
ziness [31] which quetiapine IR was often recommended
to be slowly titrated up to avoid the occurrence [27,28,47].
Meanwhile, regarding the treatment related EPS, only one
patient had transient akathisia and muscle rigidity which
resolved spontaneously later. It was also noted that the
percentage of concomitant anticholinergics use in all sub-
jects reduced at the end of the study. These findings sug-
gested that quetiapine XR improved the patients’ motor
symptoms after switching from other antipsychotics. In
our study, the metabolic disturbance associated with que-
tiapine XR was thought to be minimal since there was no
significant weight gain and increased HbA1c from base-
line to the week 12 evaluation. Compared to the previous
literature of pooled safety data from other multicenter
studies of quetiapine XR in acute schizophrenia [31], our
results suggested that the tolerability of quetiapine XR
was well in Chinese schizophrenic patients although the
findings required further studies with a larger sample size
to validate.
There are several limitations to the current study. Ini-
tially, it was a single-arm investigation without a com-
parative group for the evaluation of a possible placebo
response and may confine the interpretation of the re-
sults [48]. Besides, the open-label algorithm in which the
investigator was aware of the treatment may have influ-
enced the assessment of outcome and led to detection
bias [49,50]. Meanwhile, some participants switching for
insufficient response didn’t take full dosage of their ori-
ginal antipsychotics before recruitment and this should
be considered as one of the possible reason for the sub-
optimal efficacy of the prior treatment. Other limitations
include the small sample size of the study leading to insuf-
ficient power, and the relatively short follow-up period
compared to a previous trial [36] so that the results can
only be generalised within 12 weeks. An additional limita-
tion was that we did not measure changes in the patients’
metabolic parameters such as fasting plasma glucose, lipid
profile and waist-circumference in our investigation.
Therefore, we had difficulty in assessing the impact of the
common metabolic side effects associated with atypical
antipsychotics such as dyslipidemia [51] on the partici-
pants after the treatment of switching to quetiapine XR.
Conclusions
The results of this study indicated that quetiapine XR was
an effective and well tolerated alternative for Chinese
schizophrenic patients with previous suboptimal treat-
ment. Quetiapine XR administered once daily reached a
therapeutic level earlier through initiation of a higher dose
and rapid titration provided an advantage in making thesuccessful switch from other antipsychotics. Further stud-
ies with a larger sample size and a longer follow-up period
in the treatment of patients with schizophrenia will be re-
quired to verify the findings of this study.
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